Do Treatment Differences between Arms Affect the Main Outcome of ERSPC Rotterdam?

Journal of Urology

Volumn 194, Issue 2, 2015, Pages 336-342

  Bokhorst, Leonard P ^a   Venderbos, Lionne D F ^a   Schröder, Fritz H ^a   Bangma, Chris H ^a   Steyerberg, Ewout W ^a   Roobol, Monique J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

mass screening; mortality; outcome and process assessment (health care); prostate; prostate specific antigen

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURGERY; CONTROLLED STUDY; HIGH RISK POPULATION; HUMAN; INTERMEDIATE RISK POPULATION; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; BIOPSY; BLOOD; CLINICAL TRIAL; FOLLOW UP; INCIDENCE; MASS SCREENING; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NETHERLANDS; OUTCOME ASSESSMENT; PROCEDURES; PROGNOSIS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDY; SURVIVAL RATE; TIME; TRENDS;

PROSTATE SPECIFIC ANTIGEN;

AGED; BIOPSY; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; NETHERLANDS; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 84943362518     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2015.02.045     Document Type: Article

References (18)

1. M.J. Roobol, R. Kranse, C.H. Bangma, and et al. Screening for prostate cancer: results of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer Eur Urol 64 2013 530
2. L.P. Bokhorst, C.H. Bangma, G.J. van Leenders, and et al. Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer Eur Urol 65 2014 329
3. M. Kerkhof, M.J. Roobol, J. Cuzick, and et al. Effect of the correction for noncompliance and contamination on the estimated reduction of metastatic prostate cancer within a randomized screening trial (ERSPC section Rotterdam) Int J Cancer 127 2010 2639
4. M.J. Roobol, W.J. Kirkels, and F.H. Schröder Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands) BJU Int 92 suppl. 2003 48
5. H.J. De Koning, J. Blom, J.W. Merkelbach, and et al. Determining the cause of death in randomized screening trial(s) for prostate cancer BJU Int 92 suppl. 2003 71
6. M.J. Roobol, and F.H. Schröder European Randomized study of Screening for Prostate Cancer (ERSPC): rationale, structure and preliminary results BJU Int 92 suppl. 2003 1
7. A.V. D'Amico, R. Whittington, S.B. Malkowicz, and et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969
8. P. Autier, C. Hery, J. Haukka, and et al. Advanced breast cancer and breast cancer mortality in randomized controlled trials on mammography screening J Clin Oncol 27 2009 5919
9. T. Wolters, M.J. Roobol, E.W. Steyerberg, and et al. The effect of study arm on prostate cancer treatment in the large screening trial ERSPC Int J Cancer 126 2010 2387
10. M. Bolla, L. Collette, L. Blank, and et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial Lancet 360 2002 103
11. A. Widmark, O. Klepp, A. Solberg, and et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial Lancet 373 2009 301
12. M. Bolla, G. Van Tienhoven, P. Warde, and et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study Lancet Oncol 11 2010 1066
13. L.P. Bokhorst, R. Kranse, L.D. Venderbos, and et al. Differences in treatment and outcome after treatment with curative intent in the screening and control arms of the ERSPC Rotterdam Eur Urol 2014 Epub ahead of print
14. X. Zhu, P.J. van Leeuwen, M. Bul, and et al. Identifying and characterizing "escapes" - men who develop metastases or die from prostate cancer despite screening (ERSPC, section Rotterdam) Int J Cancer 129 2011 2847
15. M.J. Roobol, X. Zhu, F.H. Schröder, and et al. A calculator for prostate cancer risk 4 years after an initially negative screen: findings from ERSPC Rotterdam Eur Urol 63 2013 627
16. J.I. Epstein, W.C. Allsbrook Jr., M.B. Amin, and et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma Am J Surg Pathol 29 2005 1228
17. M. Zappa, D. Puliti, J. Hugosson, and et al. A different method of evaluation of the ERSPC trial confirms that prostate-specific antigen testing has a significant impact on prostate cancer mortality Eur Urol 66 2014 401
18. P.J. van Leeuwen, R. Kranse, T. Hakulinen, and et al. Impacts of a population-based prostate cancer screening programme on excess total mortality rates in men with prostate cancer: a randomized controlled trial J Med Screen 20 2013 33